Using psychostimulants in end-of-life patients with hypoactive delirium and cognitive disorders: A literature review;Utilisation des psychostimulants chez les patients en fin de vie atteints de delirium hypoactif et de troubles cognitifs: Revue de la littérature

Canadian Journal of Psychiatry

Volumn 55, Issue 6, 2010, Pages 386-393

  Elie, Dominique ^a,b,c   Gagnon, Pierre ^a,b,c,d,e   Gagnon, Bruno ^f   Giguère, Anik ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b Université Laval   (Canada)

^c Maison Michel Sarrazin   (Canada)

^d CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; METHYLPHENIDATE; PLACEBO; PSYCHOSTIMULANT AGENT; CENTRAL STIMULANT AGENT;

CINAHL; CLINICAL TRIAL; COGNITIVE DEFECT; DELIRIUM; DRUG UTILIZATION; EMBASE; EVALUATION; HUMAN; MEDICAL LITERATURE; MEDLINE; PALLIATIVE THERAPY; PROSPECTIVE STUDY; REVIEW; AGED; COGNITION DISORDERS; CONFUSION; DEPRESSIVE DISORDER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; MENTAL HEALTH; MIDDLE AGED; PSYCHOMOTOR DISORDERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TERMINAL CARE;

AGED; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; CONFUSION; DELIRIUM; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MENTAL STATUS SCHEDULE; METHYLPHENIDATE; MIDDLE AGED; PALLIATIVE CARE; PSYCHOMOTOR DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TERMINAL CARE;

EID: 77953780883     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371005500608     Document Type: Review

References (54)

1. Friedlander MM, Brayman Y, Breitbart WS. Delirium in palliative care. Oncology (Williston Park). 2004;18(12):1541-1550; discussion 51-53.
2. Gagnon P, Allard P, Masse B, et coll. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage. 2000;19(6):412-426.
3. Lawlor PG, Gagnon B, Mancini IL, et coll. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160(6):786-794.
4. Morita T, Tei Y, Tsunoda J, et coll. Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage. 2001;22(6):997-1006.
5. Trzepacz PT, Meagher DJ. Delirium. In: Levenson JL, directeur de rédaction. The American psychiatric publishing textbook of psychosomatic medicine. Washington (DC): American Psychiatric Publishing; 2005. p 91-130.
6. Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med. 2004;18(3):195-201.
7. Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics. 2002;43(3):183-194.
8. Morita T, Hirai K, Sakaguchi Y, et coll. Family-perceived distress from delirium-related symptoms of terminally ill cancer patients. Psychosomatics. 2004;45(2):107-113.
9. Platt MM, Breitbart W, Smith M, et coll. Efficacy of neuroleptics for hypoactive delirium. J Neuropsychiatry Clin Neurosci. 1994;6(1):66-67.
10. Bruera E, Neumann CM. The uses of psychotropics in symptom management in advanced cancer. Psycho-Oncology. 1998;7(4):346-358. (Pubitemid 28381144)
11. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health: the assessment and treatment of delirium. Toronto (ON): The Coalition; 2006.
12. Stiefel F, Bruera E. Psychostimulants for hypoactive-hypoalert delirium? J Palliat Care. 1991;7(3):25-26.
13. Dein S, George R. A place for psychostimulants in palliative care? J Palliat Care. 2002;18(3):196-199.
14. Homsi J, Walsh D, Nelson KA, et coll. Methylphenidate for depression in hospice practice: a case series. Am J Hosp Palliat Care. 2000;17(6):393-398.
15. Prommer E. Modafinil: is it ready for prime time? J Opioid Manag. 2006;2(3):130-136.
16. Rozans M, Dreisbach A, Lertora JJ, et coll. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol. 2002;20(1):335-339.
17. Sood A, Barton DL, Loprinzi CL. Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care. 2006;23(1):35-40.
18. Sweeney C, Bruera E. New roles for old drugs: psychostimulants. Prog Palliat Care. 2001;9(4):149-150. (Pubitemid 32894555)
19. Bruera E, Brenneis C, Paterson AH, et coll. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage. 1989;4(1):3-6. (Pubitemid 19093472)
20. Forrest WH Jr, Brown BW Jr, Brown CR, et coll. Dextroamphetamine with morphine for the treatment of postoperative pain. N Engl J Med. 1977;296(13):712-715.
21. Bruera E, Chadwick S, Brenneis C, et coll. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep. 1987;71(1):67-70.
22. Breitbart W, Rosenfeld B, Kaim M, et coll. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med. 2001;161(3):411-420.
23. Hanna A, Sledge G, Mayer ML, et coll. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer. 2006;14(3):210-215.
24. Zifko UA, Rupp M, Schwarz S, et coll. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol. 2002;249(8):983-987.
25. Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996;37(1):57-62.
26. Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry. 1995;152(6):929-931.
27. Meyers CA, Weitzner MA, Valentine AD, et coll. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16(7):2522-2527.
28. Weitzner MA, Meyers CA, Valentine AD. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci. 1995;7(3):347-350.
29. Angrist B, d'Hollosy M, Sanfilipo M, et coll. Central nervous system stimulants as symptomatic treatments for AIDS-related neuropsychiatric impairment. J Clin Psychopharmacol. 1992;12(4):268-272.
30. Fernandez F, Adams F, Levy JK, et coll. Cognitive impairment due to AIDS-related complex and its response to psychostimulants. Psychosomatics. 1988;29(1):38-46.
31. Holmes VF, Fernandez F, Levy JK. Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry. 1989;50(1):5-8.
32. Bruera E, Miller MJ, Macmillan K, et coll. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain. 1992;48(2):163-166.
33. Homsi J, Nelson KA, Sarhill N, et coll. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care. 2001;18(6):403-407.
34. Morita T, Otani H, Tsunoda J, et coll. Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer. 2000;8(2):134-137.
35. Breitbart W, Rosenfeld B, Roth A, et coll. The memorial delirium assessment scale. J Pain Symptom Manage. 1997;13(3):128-137.
36. Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res. 1988;23(1):89-97.
37. Soucy J, Low G, Gagnon B. Has anyone seen anything like this? 18-FDG PET scanning in a patient with a pre-terminal cancer and severe cognitive alterations responsive to methylphenidate [poster]. Program no 752.4. 2003 Abstract Viewer/Itinerary Planner. Washington (DC): Society for Neuroscience; 2003 [cité le 2008 avril 3]. À l'adresse : http://sfn.scholarone. com/itin2003/index.html.
38. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
39. Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005;30(2):100-107.
40. Mercadante S, Serretta R, Casuccio A. Effects of caffeine as an adjuvant to morphine in advanced cancer patients. A randomized, double-blind, placebo-controlled, crossover study. J Pain Symptom Manage. 2001;21(5):369-372.
41. Santé Canada. Feuille d'information La caféine et votre santé [Internet]. Ottawa (ON) : Santé Canada; 2005 [mis à jour le 2005 juin 3; cité le 2008 avril 30]. À l'adresse : http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/food-aliment/caffeine-fra.php.
42. Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 1983;24(1):93-98.
43. American Psychiatric Association. Manuel diagnostic et statistique des troubles mentaux. 4e édition, texte révisé. Guelfi JD, Crocq MA, Boyer P, et coll, traducteurs. Paris (FR) : Masson; 2003. [Sous-section] Delirium; p 158-171. French.
44. Smith MJ, Breitbart WS, Platt MM. A critique of instruments and methods to detect, diagnose, and rate delirium. J Pain Symptom Manage. 1995;10(1):35-77.
45. Jacobs JW, Bernhard MR, Delgado A, et coll. Screening for organic mental syndromes in the medically ill. Ann Intern Med. 1977;86(1):40-46.
46. Faust D, Fogel BS. The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis. 1989;177(1):25-31.
47. Hjermstad M, Loge JH, Kaasa S. Methods for assessment of cognitive failure and delirium in palliative care patients: implications for practice and research. Palliat Med. 2004;18(6):494-506.
48. Homsi J, Walsh D, Nelson KA. Psychostimulants in supportive care. Support Care Cancer. 2000;8(5):385-397.
49. Novartis Pharmaceuticals Corporation. Ritalin hydrochloride Ritalin-SR: prescribing information. East Hanover (NJ): The Corporation; 2006 Jun. 11 p.
50. Kaleita TA, Wellisch DK, Graham CA, et coll. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J Clin Oncol (Meeting Abstracts). 2006;24(18S):1503.
51. Kohli S, Fisher SG, Tra Y, et coll. The cognitive effects of modafinil in breast cancer survivors: a randomized clinical trial. J Clin Oncol (Meeting Abstracts). 2007;25(18S):9004.
52. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477-1502.
53. Wagner GJ, Rabkin JG, Rabkin R. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res. 1997;42(4):407-411.
54. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000;61(6):436-440.